Daniel M. Frendl, M.D., Ph.D, is a urologist with an interest in prostate cancer, benign prostatic hyperplasia, and prostate health. He is a urologic suegeon with a clinical practice that includes: • Prostate cancer diagnosis: transperineal prostate biopsy with magnetic resonance imaging and ultrasound fusion • Prostate ablation: Focal treatments for prostate cancer including high intensity focused ultrasound (HIFU), Irreversible electroporation (NanoKnife), and clinical trials for other technologies • Salvage prostate ablation: Focal ablation of prostate cancer that is locally recurrent after radiation treatment • SpaceCAR and Barrigel rectal spacer placement for patients undergoing radiation for prostate cancer • Treatments for benign prostatic hyperplasia: Rezum, UroLift, and transurethral resection (TURP) * Biopsy and resection of nonmuscle invasive bladder and urothelial cancers • Inguinal, scrotal, and penile surgery including; hydrocelectomy, orchiectory, vasectomy, circumcision • Ureteroscopy Dr. Frend is actively recruiting for the following clinical trials of focal therapy for prostate cancer: • Vapor2: a prospective multi-center, single-arm, clinical trial of transurethral water vapor ablation of Gleason Grade Group 2 (GS 3+4) prostate cancer using minimally invasive VanquishT Water Vapor Ablation, Eligible patients must have disease confined to a region surrounding an MRI visible PIRADS3 or PIRADS4 lesion Mayo Clinic's Department of Urology is one of the fow urology practices in Arizona that routinely performs transperineal prostate biopsies with advanced imaging guidance. Transperineal grostate biopsies enable more accurate detection of prostate cancer and offer a lower risk of infection than traditional transrectal biopsies. Dr. Frend's practice specializes in the transperineal approach to prostate biopsy as well as focal treatments for prostate cancer. In addition to his clinical practice. Dr.Frendl is aiso a health services researcher and is active in health policy advacacy through the American Urological Association. His current research focuses on assessing the efficacy of facal ablation treatments for prostate cancer and quality of life outcomes. Nationally, he is an active member of the Legislative Affairs Committee for the American Urological Association, Dr. Frendl received his M.D. and Ph.D. in Clinical and Population Health Research from the University of Massachusetts Medical School. He completed his training at the Massachusetts General Hospital - Harvard Urologic Surgery Residency Program. Dr. Frendl also completed a fellowship in Healthcare Policy and Administration with the Massachusetts General Hospital Physician's Organization.
ahid Punjani, M.D., M.P.H., is a urologist with a special interest and fellowship training in male infertility and men's health. Dr. Punjani attended McGill University in Canada for his Bachelor's of Science degree followed by a Post-Graduate Diploma in Clinical Research. He completed his medical school at the University of Ottawa in Canada, followed by his Urology residency at Western University in Canada. During his residency he concurrently completed a Master of Public Health Degree in Clinical Epidemiology from Harvard University. He then completed a fellowship in Male Reproductive and Sexual Medicine at Cornell University and Memorial Sloan Kettering Cancer Center in New York. During this time he also started his Doctor of Public Health Degree in Epidemiology at Columbia University in New York. Prior to starting at Mayo he spent some time working as a general urologist with a special interest in Andrology in the community. His clinical practice focuses on the treatment of male infertility, and men's health including hypogonadism, sexual dysfunction and general urology. He also has strong interests in research and education.
Girish K. Mour, M.B.B.S., is a consultant in the Division of Nephrology and Hypertension, Department of Internal Medicine at Mayo Clinic in Arizona. He joined the staff of Mayo Clinic in 2016 and holds the academic rank of assistant professor of medicine at Mayo Clinic College of Medicine and Science. Dr. Mour earned his M.B.B.S. at K.J. Somaiya Medical College in Mumbai, India. He continued his training at Nassau University Medical Center in East Meadow, New York, where he completed a residency in internal medicine, serving as chief resident, and a fellowship in nephrology. He subsequently completed a critical care fellowship at Mayo Clinic School of Graduate Medical Education, followed by a renal transplant fellowship at the University of Pittsburgh Medical Center. Dr. Mour's research focuses on reducing healthcare disparities in kidney transplantation, transplantation in elderly patients, immunosenescence in kidney transplant, and Frailty. He has given presentations both nationally and internationally and has authored numerous journal articles and abstracts. He also serves as a peer reviewer for several prominent scientific journals. Dr. Mour recently received the Paulette E. and Joseph R. Maslick Career Development Award in Transplant and Cancer Research at Mayo Clinic in Arizona. In addition to his clinical and research activities at Mayo Clinic, Arizona, Dr. Mour serves as vice chair of the Mayo Clinic School of Continuous Professional Development, is a member of the Institutional Review Board of the Mayo Clinic Office for Human Research Protection, serves on several committees of the Executive Operations Team, and serves as chair of the Transplant Center Discipline Oriented Group. Dr. Mour is a member of the American Society of Nephrology, American Society of Transplantation, and Organ Procurement and Transplantation Network, where he serves as the regional representative on the Pancreas Transplantation Committee.